Co-Diagnostics Inc (fra:C97) Share Price

Company Profile

Business description
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
Contact
2401 South Foothill Drive
Salt Lake CityUT84109
USA
T: +1 801 438-1036
https://www.codiagnostics.com
Sector
Healthcare
Stock type
Defensive
Industry
Medical Devices
Fiscal Year End
31 December 2025
Employees
132

Recommended

We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.

Brian Colello, CPA | 19 September 2025

Our Fair Value estimate once again reflects the stand-alone business and its growth potential.

Mark Taylor | 19 September 2025

Coverage of ASX listed REIT as investor interest in property continues to grow.

Yingqi Tan, CFA | 19 September 2025

Index	Last price	Change	% Change
All Ordinaries	9,088.50	34.00	-0.37%
CAC 40	7,854.61	36.39	0.47%
DAX 40	23,674.53	315.35	1.35%
Dow JONES (US)	46,142.42	124.10	0.27%
FTSE 100	9,228.11	32.45	0.35%
HKSE	26,548.27	109.76	0.42%
NASDAQ	22,470.72	209.40	0.94%
Nikkei 225	45,652.08	749.81	1.67%
NZX 50 Index	13,222.12	12.77	-0.10%
S&P 500	6,631.96	31.61	0.48%
S&P/ASX 200	8,800.00	48.50	-0.55%
SSE Composite Index	3,822.12	9.54	-0.25%